Kiora Pharmaceuticals KPRX Institutional Ownership

Updated Oct 5, 2026

Kiora Pharmaceuticals Inc (NASDAQ:KPRX) appeared in the 13F filings of 22 institutional investors for the quarter ended June 30, 2026.

• Their combined stake equaled 17.90% of outstanding shares in Q2 2026, up from 8.12% in Q1 2026.
• Total shares held in KPRX rose 225.95% from Q1 2026; the number of holders rose 37.50% from Q2 2025.
• Of the 22 holders of KPRX in Q2 2026, 13 added to their positions, 2 reduced their stakes and 7 left their positions unchanged.
• Combined, institutional investors held 1.11Mn shares of KPRX as of Q2 2026, up 766.38K from the prior quarter and up 173.72K from a year earlier.
• Perceptive Advisors LLC held the largest position in KPRX at 438.47K shares as of June 30, 2026, or 7.10% of shares outstanding.
• Among existing holders, the largest additions to Kiora Pharmaceuticals in Q2 2026 came from Citadel Advisors LLC (+66.48K shares), Caitong International Asset Management Co., Ltd (+1.81K shares) and UBS Group AG (+660 shares).
• Holders that trimmed the most shares of Kiora Pharmaceuticals in Q2 2026 while keeping a position were Geode Capital Management, LLC (-21.13K shares) and Tower Research Capital LLC (-158 shares).
• Kiora Pharmaceuticals' 10 largest institutional shareholders as of Q2 2026 were Perceptive Advisors LLC (438.47K shares), ADAR1 Capital Management, LLC (167.94K shares), Citadel Advisors LLC (116.01K shares), Two Sigma Investments, LP (88.79K shares), Millennium Management LLC (74.2K shares), HRT Financial LP (58.61K shares), Renaissance Technologies LLC (29.82K shares), Geode Capital Management, LLC (26.72K shares), Vanguard Capital Management LLC (19.86K shares) and Scientech Research LLC (18.75K shares), per Business Quant data.